A prospective and retrospective multicenter cohort study of Daclatasvir + Asunaprevir combination therapy for chronic hepatitis C with and without liver cirrhosis

A prospective and retrospective multicenter cohort study of Daclatasvir + Asunaprevir combination therapy for chronic hepatitis C with and without liver cirrhosis - SMART-C V3

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016769

Enrollment

1000

Registered

2015-03-11

Start date

2015-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C with and without liver cirrhosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Those who gave written informed consent for participation 2) Those with HCV-RNA genotype 1 or serotype 1 3) Those who are not contraindicated for Daclatasvir and Asunaprevir 4) Those not suitable or intolerant for interferon therapy

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
sustained virological response	—

Countries

Japan

Contacts

Public ContactTatsuya Minami

The University of Tokyo Hospital Department of Gastroenterology

tminami-tky@umin.ac.jp03-3815-5411

Outcome results